title: Liver cancer drug is rejected for routine NHS use but will remain in Cancer Drugs Fund.
authors.affiliation: London.
authors.forename: Ingrid
authors.initials: I
authors.lastname: Torjesen
mesh_terms: D026683:Advisory Committees; D000970:Antineoplastic Agents / Q000191:economics* / Q000600:supply & distribution / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D006801:Humans; D008099:Liver / Q000473:pathology; D008113:Liver Neoplasms / Q000188:drug therapy / Q000473:pathology; D009536:Niacinamide / Q000031:analogs & derivatives* / Q000191:economics / Q000600:supply & distribution / Q000627:therapeutic use; D010671:Phenylurea Compounds / Q000191:economics* / Q000600:supply & distribution / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors; D019057:Quality-Adjusted Life Years; D000077157:Sorafenib; D006113:United Kingdom
chemical_list: D000970:Antineoplastic Agents; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D009536:Niacinamide; D000077157:Sorafenib